Why the study?
Increasing attention is being paid to qualitative characteristics of von Willebrand factor alongside quantitative measures in von Willebrand disease.
Does the measurement of vWF:CBAI and vWF:CBAIII improve the diagnostic distinction between healthy individuals and patients with type 1 von Willebrand disease?
Does the measurement of vWF:CBAI and vWF:CBAIII improve the diagnostic distinction between healthy individuals and patients with type 1 von Willebrand disease?
Testing for vWF binding capacity to collagen types I and III may serve as a useful additional diagnostic tool to distinguish patients with type 1 von Willebrand disease from healthy individuals.
Answers are grounded in this paper and cite their sources.
vWF collagen-binding assays may refine type 1 vWD subtyping; leaves open routine diagnostic adoption pending confirmatory studies.
Introduction. Along with the quantitative characteristics of the von Willebrand factor (vWF), more attention is paid to its qualitative characteristics in patients with von Willebrand disease (vWD). Aim — to evaluate the frequency of vWF binding capacity disorders with type I collagen (vWF:CBAI) and type III collagen (vWF:CBAIII) in patients diagnosed with type 1 vWD and the diagnostic capabilities of these tests. Material and methods. The prospective study included 224 female patients with previously diagnosed vWD type 1. The following tests were performed in the venous blood sample: von Willebrand factor antigen (vWF:Ag), vWF:CBAI, vWF:CBAIII. The control group consisted of 80 healthy female blood donors. Results. In the control group, the values of vWF:CBAI and vWF:CBAIII did not exceed the reference intervals. A decrease in vWF:CBAI was detected in 133 (59.4 %) patients and vWF:CBAIII in 26 (11.6 %) patients. An isolated decrease in vWF:CBAI was detected in 87 (38.8 %) patients . An isolated decrease in vWF:CBAIII was less common — in 6 (2.7 %) patients. Conclusion. The study of vWF:CBAI and vWF:CBAIII appears to be useful as an additional diagnostic test to improve the distinction between healthy individuals and those with VWD.
No takes yet. Share an insight, caveat, or question.
Колосков et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: